Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women"

Transcription

1 Maturitas 50 (2005) Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women Toshiyuki Yasui a,, Hirokazu Uemura a, Yuka Umino a, Masaya Takikawa a, Seiichiro Saito a, Akira Kuwahara a, Toshiya Matsuzaki a, Masahiko Maegawa a, Hiroyuki Furumoto a, Masakazu Miura b, Minoru Irahara a a Department of Obstetrics and Gynecology, School of Medicine, University of Tokushima, Tokushima , Japan b Department of Pharmaceutical Research, Mitsubishi Kagaku Bio-Clinical Laboratories Inc., Tokyo 174, Japan Received 26 August 2003; received in revised form 19 January 2004; accepted 1 March 2004 Abstract Objective: The objective of this study was to determine the relationships of serum estrogen levels after hormone replacement therapy (HRT) every other day and every day with body mass index (BMI) in postmenopausal and bilaterally ovariectomized women. Methods: Eighty-six postmenopausal and 51 bilaterally ovariectomized women who had been suffering from vasomotor symptoms such as hot flush or atrophy of the vagina were randomly treated with HRT every other day or every day. Seventy-four patients received oral administration of mg conjugated equine estrogen (CEE) and 2.5 mg medroxyprogesterone acetate (MPA) every other day, and 63 patients received oral administration of mg CEE and 2.5 mg MPA every day as conventional HRT. Results: Eighty-four postmenopausal and 50 bilaterally ovariectomized women completed this study. Serum estradiol levels after HRT every day in postmenopausal and bilaterally ovariectomized women were significantly (P <0.05 and <0.01, respectively) correlated with BMI, while those after HRT every other day were not correlated with BMI. The differences between estradiol levels after 12 months of treatment and initial estradiol levels were also significantly (P <0.01) correlated with BMI in both postmenopausal and bilaterally ovariectomized women who received HRT every day but not in women who received HRT every other day. Serum estrone level after HRT every day and the difference between estrone level after 12 months of treatment and initial estrone level were significantly (P <0.05 and <0.01, respectively) correlated with BMI only in bilaterally ovariectomized women. Conclusion: Serum estradiol levels after HRT every day increase more in overweight women than in non-overweight postmenopausal and bilaterally ovariectomized women. The results of the present study regarding the relationship between serum estradiol levels after HRT and BMI should be useful for selecting dosages of drugs to be used in HRT Elsevier Ireland Ltd. All rights reserved. Keywords: Serum estrogen level; Hormone replacement therapy; Ovariectomized women 1. Introduction Corresponding author. Fax: address: (T. Yasui). The effectiveness of hormone replacement therapy (HRT) for treatment of bone loss as well as for relief /$ see front matter 2004 Elsevier Ireland Ltd. All rights reserved. doi: /j.maturitas

2 20 T. Yasui et al. / Maturitas 50 (2005) of vasomotor symptoms and vaginal atrophy in postmenopausal and bilaterally ovariectomized women is well established [1]. The study of Women s Health Initiative (WHI) has stopped because overall health risks exceeded benefits from the use of combined conjugated equine estrogen (CEE) at a dosage of mg per day and medroxyprogesterone acetate (MPA) at a dosage of 2.5 mg per day, and the results indicated that this regimen should not be initiated or continued for the primary prevention of coronary heart disease [2]. The fact that 69% of the postmenopausal women who participated in that trial had a high body mass index (more than 25.0 kg/m 2 ) suggests that body mass index (BMI) may have effects on risks to health and benefits for health of HRT. It is known that endogenous estradiol levels in women with high BMI and those with low BMI are different. Low endogenous estradiol levels in postmenopausal women were related to appearance of hot flush [3] and osteoporosis [4,5]. The relative risk for breast cancer in women with the highest endogenous estradiol level was higher than that in women with the lowest estradiol level [6,7]. Several studies have also shown that BMI is related to various beneficial effects and risks after HRT. It has been reported that HRT reduced the risk of hip fracture more in women with low BMI than in women with high BMI [8]. Genital bleeding after HRT was found to be more frequent in overweight and obese postmenopausal women than in postmenopausal women with normal BMI [9]. However, the relationship between serum estrogen level after CEE treatment and BMI has not been fully investigated. In the present study, we precisely measured serum levels of estradiol and estrone using a highly sensitive and specific assay system in postmenopausal and bilaterally ovariectomized women before and after HRT with CEE and MPA every other day or every day, and we determined the relationships between serum levels of estradiol and estrone after HRT and BMI in these women. 2. Subjects and methods 2.1. Subjects Eighty-six postmenopausal and 51 bilaterally ovariectomized women who had been suffering from vasomotor symptoms such as hot flush or atrophy of the vagina were recruited for this study from the outpatient clinic of the Department of Obstetrics and Gynecology, Tokushima University Hospital, and informed consent for participation in the study was obtained from each woman. Reviews of medical histories and the results of physical examinations and blood chemistry tests showed that all of the women were in good health and that none of the women had previously received any medication before the commencement of hormonal therapy. None of women had a history of estrogen-related cancer, and all women showed negative results on a mammogram and had a transvaginal ultrasonographically normal-appearing endometrium. No abnormalities were found in endometrial smears in any of the women. Serum levels of estradiol and estrone were measured before and at 12 months after the start of HRT, and baseline levels of serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were measured before treatment. Eligible women were randomly treated with low-dose or conventional HRT. Seventy-four women received oral administration of mg CEE (Premarin, Wyeth) and 2.5 mg MPA (Provera, Upjohn) every other day, and 63 women received oral administration of mg CEE and 2.5 mg MPA every day as conventional HRT. As a preliminary study, serum levels of estradiol and estrone were measured before and at 6, 15 and 24 h after administration of CEE and MPA at 6 and 12 months after the start of HRT every day in eight women and before and at 6, 15, 24, 30 and 48 h after administration of CEE and MPA at 6 and 12 months after the start of HRT every other day in seven women. Endometrial smear and transvaginal ultrasonography were used for endometrial assessment during treatment, and no abnormalities were found in any of the women. Compliance was assessed by pill count, and side-effects were ascertained by questionnaires at 4-week intervals Measurements of estradiol and estrone We have developed a highly sensitive and specific assay for precise measurement of serum estrone and estradiol levels [10]. Estradiol and estrone, obtained by solid-phase extraction using a Sep pak

3 T. Yasui et al. / Maturitas 50 (2005) tc18 cartridge, were purified by high-performance liquid chromatography (HPLC). Estrone and estradiol were sufficiently separated from other steroid hormones. Then levels of estradiol and estrone were measured by radioimmunoassays. Antiserum, 125 I-labeled reagents and a precipitating reagent were obtained from Diagnostic System Laboratories (Texas, USA). The antiserum of estradiol did not react with the corticosterone and aldosterone that were eluted close to a 17 -estradiol by HPLC. The limits of detection of estradiol and estrone, defined as mean blank measurement minus 2S.D. (2 standard deviation of zero bound), were 1.04 and 0.64 pg/ml, respectively. The intra-assay coefficient of variation (CV) of estradiol and that of estrone were 8.5 and 19.5%, respectively (mean serum estradiol concentration: 5.3 pg/ml; mean serum estrone concentration: 22.0 pg/ml). Serum levels of estradiol during the period of treatment with CEE determined by this method were strongly correlated with those determined by gas chromatography mass spectrometry, which was performed at LAB GmbH & Co., Neu-Ulm, Germany. In the normal menstrual cycle, mean levels of estradiol measured by this method in the follicular and preovulatory phases were similar to those reported previously. Based on the finding that estradiol level remained almost constant between 12 and 18 h after single administration of CEE, fasting blood samples in patients treated every other day and every day were drawn h after taking CEE [10] and the assay was run at the same time. The blood samples were centrifuged at 4 C, and the serum samples obtained were frozen until analysis Measurements of serum LH and FSH Blood samples were taken from women at the time of serum estradiol measurement. Serum levels of LH and FSH were measured using radioimmunoassay kits obtained from Daiichi Radioisotope Laboratories (Tokyo, Japan). In these assays, standards of LH and FSH were calibrated by WHO 1st IRP-LH and WHO 2nd IRP-hPG, respectively. The intraassay CV of LH and that of FSH were 6.5 and 4.1%, respectively, and the inter-assay CV of LH and that of FSH were 6.1 and 6.0%, respectively (mean serum LH: 23.5 IU/l; mean serum FSH: 71.8 IU/l) Statistical analysis Data are presented as means ± S.D.s. Statistical analyses among groups were performed by ANOVA. Serum estradiol and estrone levels at each dose in postmenopausal and bilaterally ovariectomized women were tabulated using descriptive statistics and correlated with BMI using linear regression analysis. The differences between serum estradiol and estrone concentrations after HRT and initial concentrations at each dose were also tabulated using descriptive statistics and correlated with BMI using linear regression analysis. P-values <0.05 were considered to be statistically significant. 3. Results Eighty-four of the 86 postmenopausal women and 50 of the 51 bilaterally ovariectomized women completed the 1-year study. There was no difference between compliance of women who received HRT every day and that of women who received HRT every other day. Two of the 86 postmenopausal women treated every day dropped out of the study because of prolonged unscheduled bleeding, and one of the 51 bilaterally ovariectomized women treated every other day dropped out of the study for reasons unrelated to treatment. Baseline characteristics are presented in Table 1. The body mass index was calculated as the weight in kilograms divided by the square of height in meters (kg/m 2 ). Fig. 1 shows the pharmacokinetics of estradiol and estrone after the administration of CEE and MPA every day and every other day as a preliminary study. Mean serum estradiol level in eight women who had undergone HRT every day for 12 months was 31.7 pg/ml at 15 h after administration of CEE and MPA and had decreased to 21.1 pg/ml at 24 h after administration, while that in seven women who had undergone HRT every other day for 12 months was 21.3 pg/ml at 15 h after administration of CEE and MPA and had decreased to 15.8 and 6.7 pg/ml at 24 and 48 h after administration, respectively. On the other hand, mean serum estrone level in eight women who had undergone HRT every day for 12 months was pg/ml at 15 h after administration of CEE and MPA and had decreased to pg/ml at 24 h after administration,

4 22 T. Yasui et al. / Maturitas 50 (2005) Table 1 Characteristics of women at the initial examination Postmenopausal women Bilaterally ovariectomized women HRT every day HRT every other day HRT every day HRT every other day No. of patients Age (years) 53.7 ± ± ± 5.7 a,c 50.1 ± 6.7 b,d Years since menopause (years) 4.9 ± ± ± 3.2 d 5.1 ± 6.9 BMI 23.3 ± ± ± ± 2.6 Estrone (pg/ml) 20.3 ± ± ± ± 13.0 Estradiol (pg/ml) 5.3 ± ± ± ± 1.9 b,d LH (IU/l) 30.8 ± ± ± ± 12.8 FSH (IU/l) 86.1 ± ± ± ± 31.7 Means ± S.D., BMI: body mass index. a P<0.01. b P<0.05 vs. postmenopausal women who received HRT every day. c P<0.01. d P<0.05 vs. postmenopausal women who received HRT every other day. while that in seven women who had undergone HRT every other day for 12 months was pg/ml at 15 h after administration of CEE and MPA and had decreased to 73.8 and 36.6 pg/ml at 24 and 48 h after administration, respectively. Table 2 shows serum estradiol and estrone levels after 12 months in all women treated every other day and every day. The mean levels of estradiol after 12 months in postmenopausal women treated every other day and every day were 14.3 and 31.4 pg/ml, respectively, and those in bilaterally ovariectomized women treated every day and every day were 13.2 and 30.3 pg/ml, respectively. The mean levels of estrone after 12 months in postmenopausal women treated every other day and every day were 72.9 and pg/ml, respectively, and those in bilaterally ovariectomized women treated every day and every day were 75.4 and pg/ml, respectively. There was no significant difference between serum levels of estradiol or between serum levels of estrone at 12 months after the start of treatment in the two treatment groups. Table 3 shows the correlations between endogenous estrone and estradiol levels and BMI. There was no correlation of endogenous estrone or estradiol level with BMI before treatment in either of the groups. There were no significant differences between BMI before and that at 12 months after HRT every day or every other day. The correlations of serum estradiol levels with BMI at 12 months after HRT every day and HRT every other day in postmenopausal and bilaterally ovariectomized women are shown in Fig. 2. The serum estradiol level after HRT every day in postmenopausal women showed a significant (P <0.05) positive correlation with BMI. The Table 2 Serum estrone and estradiol levels in women who received HRT every other day and every day Means ± S.D. Estradiol (pg/ml) Estrone (pg/ml) Postmenopausal women HRT every day 31.4 ± ± 74.7 HRT every other day 14.3 ± ± 37.4 Bilaterally ovariectomized women HRT every day 30.3 ± ± 61.7 HRT every other day 13.2 ± ± 29.3 Serum estrogen levels are measured in 84 postmenopausal women (HRT every day: 38 women; HRT every other day: 46 women) and 50 bilaterally ovariectomized women (HRT every day: 23 women; HRT every other day: 27 women). Fasting blood samples were drawn h after HRT.

5 Fig. 1. Pharmacokinetics of estradiol and estrone in postmenopausal women after 6 months and 12 months of HRT every day and every other day. Closed diamonds are values after HRT every day, and closed square are values after HRT every other day. Data are presented as means ± S.E.s. Serum levels of estradiol and estrone were measured before and at 6, 15 and 24 h after administration of CEE and MPA at 6 and 12 months after the start of HRT every day in 8 postmenopausal women and before and at 6, 15, 24, 30 and 48 h after administration of CEE and MPA at 6 and 12 months after the start of HRT every other day in seven postmenopausal women. T. Yasui et al. / Maturitas 50 (2005)

6 24 T. Yasui et al. / Maturitas 50 (2005) Table 3 Correlations between levels of endogenous estrogens and BMI Postmenopausal women Bilaterally ovariectomized women HRT every day HRT every other day HRT every day HRT every other day Coefficient P-value Coefficient P-value Coefficient P-value Coefficient P-value Estrone (pg/ml) Estradiol (pg/ml) BMI: body mass index; serum estrogen levels are measured in 84 postmenopausal women and 50 bilaterally ovariectomized women. Fig. 2. Correlations between serum estradiol levels at 12 months after HRT every day (upper panel) and every other day (lower panel) and BMI in postmenopausal and bilaterally ovariectomized women. Serum estradiol level in 38 postmenopausal women who received HRT every day showed a significant (P <0.05) positive correlation with BMI (the relationship being expressed by the following equation: estradiol level = 1.21 BMI ; R = 0.402). Estradiol level in 23 bilaterally ovariectomized women who received HRT every day showed a significant (P <0.01) positive correlation with BMI (the relationship being expressed by the following equation: estradiol level = BMI 7.642; R = 0.565).

7 T. Yasui et al. / Maturitas 50 (2005) serum estradiol level after HRT every day in bilaterally ovariectomized women also showed a significant (P < 0.01) positive correlation with BMI. On the other hand, serum estradiol levels after HRT every other day in postmenopausal and bilaterally ovariectomized women were not correlated with BMI. The differences between estradiol levels after 12 months of treatment and initial estradiol levels ( -estradiol) in postmenopausal and bilaterally ovariectomized women who received HRT every day showed a significant (P < 0.01) positive correlation with BMI (data not shown). On the other hand, -estradiol in Fig. 3. Correlations of serum estrone level after HRT every day with BMI in 23 bilaterally ovariectomized women (upper panel) and 38 postmenopausal women (lower panel). Serum estrone level in bilaterally ovariectomized women who received HRT every day showed a significant (P <0.05) positive correlation with BMI (the relationship being expressed by the following equation: estrone level = BMI ; R = 0.504).

8 26 T. Yasui et al. / Maturitas 50 (2005) postmenopausal and bilaterally ovariectomized women treated with every other day were not correlated with BMI. As shown in Fig. 3, the serum estrone level after HRT every day in bilaterally ovariectomized women showed a significant (P <0.05) positive correlation with BMI. The difference between estrone levels after HRT and initial estrone levels ( -estrone) in bilaterally ovariecstomized women treated with HRT every day also showed a significant (P < 0.01) positive correlation with BMI (data not shown). On the other hand, neither the serum estrone level after HRT nor -estrone was correlated with BMI in postmenopausal women treated HRT every day. 4. Discussion Little is known about estradiol levels in women after treatment with CEE because CEE is a complex of at least 10 natural estrogens, including estrone sulfate, equilin sulfate and 17 -estradiol sulfate, and precise measurement of the serum estradiol level during CEE treatment is difficult. Estrone sulfate, which is the major component, is readily absorbed from the gastrointestinal tract, and a fraction of it is rapidly converted into circulating unconjugated estrone and unconjugated 17 -estradiol, which is the most biologically active estrogen [11]. Extraction of sex steroid hormones in serum before the assay is needed for measurement of serum estradiol levels in postmenopausal and bilaterally ovariectomized women receiving CEE for HRT. Lobo et al. reported that serum estradiol levels after 25 days of treatment with CEE at dosages of 0.3 mg and mg per day increased to 18.5 and 39.4 pg/ml, respectively [12], and Jurgens et al. reported that serum estradiol level after administration of CEE at a dosage of mg per day for one month increased to 20.0 pg/ml [13]. These data are consistent with those obtained in the present study. However, serum estradiol levels after long-term treatment with oral CEE have not been reported due to technical difficulties in clinical assays. We have developed a highly sensitive and specific assay using HPLC for purification and a radioimmunoassay for measurement of serum estrone and estradiol levels [10], and we have precisely measured both endogenous estrogen levels and estrogen levels after CEE treatment using this assay. In a pharmacokinetics study, we found that both the levels of estradiol and estrone peaked at about 15 h after CEE administration and that the levels of estradiol and estrone in women treated with CEE every day were about times higher than those in women every other day. After menopause, peripheral aromatization of gonadal steroid hormones in adipose tissue is the primary source of endogenous estrogen. Extraglandular production of estrogen in adipose tissue and circulating estrogen levels increase with increase in body mass in postmenopausal women. Lower levels of endogenous estradiol and estrone have been reported to be found in women with frequent hot flashes, and flushing is more likely in thin women [3]. It has been found that obese postmenopausal women had a significantly higher vertebral BMD than did non-obese women [14] and that a higher endogenous estradiol level is associated with increased BMD, reduced bone loss and reduced fracture incidence in elderly women [4,5]. A high endogenous estradiol level has also been reported to be related to the relative risk for breast cancer in women [6,7]. We did not find a correlation between endogenous estrogen levels and BMI in the subjects in the present study, probably because the subjects in the present study were younger than subjects in previous studies. In the present study, estradiol level after HRT every day showed a significant positive correlation with BMI in postmenopausal and bilaterally ovariectomized women. Moreover, the difference between estradiol level after HRT every day and endogenous estradiol level also showed a significant positive correlation with BMI in these women. Thus, serum estradiol level after HRT every day increases more in obese than in non-obese postmenopausal and bilaterally ovariectomized women. The biological mechanism underlying the effect of HRT on body mass is complex. It might be related to the expression level of estrogen receptors (ERs) in adipose tissue, and the expression levels of ERs in obese women and thin women might be different. Adipose tissue has been reported to increase in female and male ER- knockout mice [15,16]. In obese women, the ER- expression level might be low and there might be a reciprocal relationship between ER- expression level and serum estradiol level. In obese women, a very high estradiol level, exceeding the response threshold, after HRT every day may have not only beneficial effects but also adverse

9 T. Yasui et al. / Maturitas 50 (2005) effects on various parts of the body. Buyuk et al. demonstrated that there is a trend toward a relation between BMI and breakthrough bleeding in postmenopausal women receiving HRT [9]. Women receiving estrogen progestin treatment in the WHI trial had increased relative risks for cardiovascular events and breast cancer. Mean body mass indices at the start of that trial in both the estrogen progestin group and placebo group were 28.5 kg/m 2, and the proportions of women with BMI of more than 25.0 kg/m 2 were 69.5% in the estrogen progestin group and 69.2% in the placebo group [2]. Thus, higher estrogen level due to the additional exogenous estrogen in women with high BMI may be related to these risks. On the other hand, an appropriate estradiol level for response thresholds after HRT every day may have beneficial effects for non-obese women. The association between use of HRT and hip fracture risk was found to be stronger in thin women in a population-based case-control study [8]. Rodriguez et al. found in an observation study that the inverse association between use of estrogen and coronary heart disease mortality was strongest for thin women (BMI < 22 kg/m 2 ) and that estrogen treatment did not reduce the risk of coronary heart disease for obese women whose BMI was more than 30 kg/m 2 [17]. Women with large body mass may have already gained the maximum effect due to increased extraglandular production of estrogen in adipose tissue, and a protective effect of HRT in women with a large body mass has not been observed. HRT resulted in an increase in estrogen to an appropriate level in thin women with frequent hot flashes whose endogenous estrogen level was low, and HRT may improve vasomotor symptoms and quality of life in such women. However, several observational studies have suggested that there are more risks of HRT in thin women than in obese women. An increased risk of breast cancer associated with hormone use has been found for postmenopausal thin women but not for postmenopausal women with high BMI [18]. Schairer et al. demonstrated that relative risk of breast cancer increased in women with a BMI not exceeding 24.4 kg/m 2 but that risk of breast cancer in heavier women (BMI of more than 24.4 kg/m 2 ) was not changed by treatment with estrogen alone or estrogen and progestin [19]. Michaelsson et al. reported that estrogens such as estradiol and conjugated estrogen were most strongly associated with breast cancer as well as protection of hip fracture in relatively lean women [8]. In the present study, both the serum estrone level and the difference between estrone level after HRT every day and endogenous estrone level showed significant positive correlations with BMI in bilaterally ovariectomized women but not in postmenopausal women. It is well known that estrone, which makes up the largest amount of estrogen produced in postmenopausal women, is a result of mainly peripheral conversion of androstenedione in adipose tissue. Thus, the conversion is greater in obese women, and an increased circulating level of estrone is thought to contribute to the association between obesity and endometrial proliferation and cancer. The significant correlation found in bilaterally ovariectomized women may have been because endogenous estrone derived from androstenedione in the adrenal gland and exogenous estrone after CEE administration are only related. On the other hand, the postmenopausal ovary has been shown to be an androgen-producing gland and to produce estrone and estradiol due to aromatization [20]. In postmenopausal women, endogenous estrone in the ovaries together with that produced by the adrenal gland and exogenous estrone after CEE administration are mixed, and a relationship between serum estrone level and BMI might therefore not be clearly observed. Many efforts have been made worldwide to develop low-dose HRT regimens that are effective for achieving long-term benefits of estrogens while minimizing side effects and risks [21 26]. The results of the WHI trial have also indicated that results do not apply to lower dosages of CEE and MPA. The HRT regimen used in the present study, consisting of mg of CEE and 2.5 mg of MPA administered every other day, could be regarded as low-dose HRT. Neither the serum estradiol levels after HRT every other day nor the difference between estradiol levels after HRT every other day and endogenous estradiol levels were correlated with BMI in our study. In obese women, low-dose HRT may be recommended if estrogen levels after low-dose HRT reach response thresholds. It is important to consider the type of hormone regimen as well as the characteristics of each women such as BMI. Our study has several limitations. Since the HRT regimen used in our study was continuous oral administration of CEE and MPA, the results regarding the

10 28 T. Yasui et al. / Maturitas 50 (2005) relationship between serum estrogen levels after CEE and BMI are not applicable to administration of other types of estrogen (e.g., 17 -estradiol administered transdermally, micronized estradiol). Further study using other estrogens is needed. In addition, the range of body mass indices in the subjects in the present study was relatively small. Further study using subjects with a broader range of body mass indices is needed. It is important to titrate the dose of a drug to the needs of the individual. Adjustment of estrogen dosage in women who have a high BMI could be a means for reducing the incidence of breakthrough bleeding in women who are on HRT. Low-dose HRT might be appropriate for obese women. A highly sensitive and specific estrogen assay such as that used in this study is not yet widely available for clinical use. If this estrogen assay is used, estradiol levels in obese women may be an important indicator during HRT every day. The HRT regimen must be based on the needs of each woman and ensure that serum estradiol in the postmenopausal woman receiving HRT will be maintained at an appropriate level. In conclusion, serum estradiol levels after HRT with CEE and MPA every day increase more in overweight than in non-overweight postmenopausal and bilaterally ovariectomized women. The results of the present study regarding the relationship between BMI and estrogen levels during HRT should be useful for choosing appropriate HRT regimens for postmenopausal women. References [1] Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330: [2] Writing group for the women s health initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288: [3] Erlik Y, Meldrum DR, Judd HL. Estrogen levels in postmenopausal women with hot flashes. Obstet Gynecol 1982;59: [4] Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med 1998;339: [5] Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA, Cummings SR. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab 1998;83: [6] Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Ann Intern Med 1999;130: [7] Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 2002; 287: [8] Michaelsson K, Baron JA, Johnell O, Persson I, Ljunghall S. Swedish hip fracture study group. Variation in the efficacy of hormone replacement therapy in the prevention of hip fracture. Osteoporos Int 1998;8: [9] Buyuk E, Gurler A, Erenus M. Relationship between circulating estradiol levels, body mass index, and breakthrough bleeding in postmenopausal women receiving hormone replacement therapy. Menopause 1998;5:24 7. [10] Yasui T, Yamada M, Kinoshita H, et al. Combination of automatic HPLC-RIA method for determination of estrone and estradiol in serum. J Clin Lab Anal 1999;13: [11] Lobo RA. Absorption and metabolic effects of different types of estrogens and progestogens. Obstet Gynecol Clin North Am 1987;14: [12] Lobo RA, Brenner P, Mishell DR. Metabolic parameters and steroid levels in postmenopausal women receiving lower doses of natural estrogen replacement. Obstet Gynecol 1983;62:94 8. [13] Jurgens RW, Downey LJ, Abernethy WD, Cutler NR, Conrad J. A comparison of circulating hormone levels in postmenopausal women receiving hormone replacement therapy. Am J Obstet Gynecol 1992;167: [14] Rico H, Arribas I, Casanova FJ, Duce AM, Hernandez ER, Cortes-Prieto J. Bone mass, bone metabolism, gonadal status and body mass index. Osteoporos Int 2002;13: [15] Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. Increased adipose tissue in male and female estrogen receptor- knockout mice. Proc Natl Acad Sci USA 2000;97: [16] Cooke PS, Heine PA, Taylor JA, Lubahn DB. The role of estrogen and estrogen receptor- in male adipose tissue. Mol Cell Endocrinol 2001;178: [17] Rodriguez C, Calle E, Patel A, Tatham L, Jacobs E, Thun M. Effect of body mass on the association between estrogen replacement therapy and mortality among elderly US women. Am J Epidemiol 2001;153: [18] Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350: [19] Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen progestin replacement and breast cancer risk. JAMA 2000;283: [20] Adashi EY. The climacteric ovary as a functional gonadotropin-driven androgen-producing gland. Fertil Steril 1994;62:20 7.

11 T. Yasui et al. / Maturitas 50 (2005) [21] Lobo RA, Whitehead MI. Is low-dose hormone replacement therapy for postmenopausal women efficacious and desirable? Climacteric 2001;4: [22] Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Picker JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75: [23] Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287: [24] Lobo RA, Bush T, Carr BR, Picker JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001;76: [25] Picker JH, Yeh IT, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;76: [26] Archer DF, Dorin M, Lewis V, Schneider DL, Picker JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:

Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11

Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Clinical Pearl Post Women's Health Initiative Menopausal Women and Hormone Therapy by JoAnn V. Pinkerton,

More information

SERMS, Hormone Therapy and Calcitonin

SERMS, Hormone Therapy and Calcitonin SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings

More information

Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki-city, Osaka , Japan. Pituitary gonadotropin, Clinical managament

Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki-city, Osaka , Japan. Pituitary gonadotropin, Clinical managament Original Article Adequate Reduction Degree of Pituitary Gonadotropin Level in the Clinical Management of Short-Term Hormone Replacement Therapy of Women with Menopausal Symptoms Department of Obstetrics

More information

Outline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013

Outline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013 Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort

More information

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen

More information

MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?

MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE? MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early

More information

A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W

A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W Record Status This is a critical abstract of an economic evaluation

More information

PROSPECTIVE STUDIES HAVE

PROSPECTIVE STUDIES HAVE ORIGINAL CONTRIBUTION Serum Estradiol Level and Risk of Breast Cancer During Treatment With Steven R. Cummings, MD Tu Duong, MA Emily Kenyon, PhD Jane A. Cauley, DrPH Malcolm Whitehead, MB,BS, FRCOG Kathryn

More information

Women s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School

Women s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help

More information

Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals

Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health

More information

25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?

25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy? Research Subcutaneous estrogen replacement therapy. Jones SC. Journal of Reproductive Medicine March, 2004; 49(3):139-142. Department of Obstetrics and Gynecology, Keesler Medical Center, Keesler Air Force

More information

Hormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare

Hormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare Hormones friend or foe? Undertreatment and quality of life Anette Tønnes Pedersen MD, Ph.D. Consultant, Associate professor Dept. Of Gynecology / Fertility Clinic Rigshospitalet No conflicts of interest

More information

WHI Estrogen--Progestin vs. Placebo (Women with intact uterus)

WHI Estrogen--Progestin vs. Placebo (Women with intact uterus) HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric

More information

Relationship between bone resorption and adrenal sex steroids and their derivatives in oophorectomized women

Relationship between bone resorption and adrenal sex steroids and their derivatives in oophorectomized women FERTILITY AND STERILITY VOL. 82, NO. 6, DECEMBER 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Relationship between bone

More information

HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer

HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer -- PART 1 -- Definitions HRT hormone replacement therapy HT genome therapy ERT estrogen replacement therapy ET estrogen EPT estrogen progesterone therapy

More information

Postmenopausal hormone therapy and cancer risk

Postmenopausal hormone therapy and cancer risk International Congress Series 1279 (2005) 133 140 www.ics-elsevier.com Postmenopausal hormone therapy and cancer risk P. Kenemans*, R.A. Verstraeten, R.H.M. Verheijen Department of Obstetrics and Gynaecology,

More information

PERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.

PERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW. PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas

More information

HRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College

HRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College HRT in Perimenopausal Women Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College 1 This is the Change But the CHANGE is not a disease 2 Introduction With a marked increase in longevity, women now

More information

The Tissue-Selective Estrogen Complex (TSEC): A Promising New Therapy for Menopausal Symptoms and Postmenopausal Osteoporosis

The Tissue-Selective Estrogen Complex (TSEC): A Promising New Therapy for Menopausal Symptoms and Postmenopausal Osteoporosis Curr Obstet Gynecol Rep (2012) 1:50 58 DOI 10.1007/s13669-012-0007-6 MANAGEMENT OF MENOPAUSE (K-E HUANG, SECTION EDITOR) The Tissue-Selective Estrogen Complex (TSEC): A Promising New Therapy for Menopausal

More information

Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms

Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms Photo (compulsory) Steven R Goldstein, MD 1 ; Ginger D Constantine, MD 2 ; David F Archer, MD 3 ; James H Pickar,

More information

Estrogens and progestogens

Estrogens and progestogens Estrogens and progestogens Estradiol and Progesterone hormones produced by the gonads are necessary for: conception embryonic maturation development of primary and secondary sexual characteristics at puberty.

More information

Copyright, 1995, by the Massachusetts Medical Society

Copyright, 1995, by the Massachusetts Medical Society Copyright, 1995, by the Massachusetts Medical Society Volume 332 JUNE 15, 1995 Number 24 THE USE OF ESTROGENS AND PROGESTINS AND THE RISK OF BREAST CANCER IN POSTMENOPAUSAL WOMEN GRAHAM A. COLDITZ, M.B.,

More information

Tissue-selective estrogen complexes for postmenopausal women. BMS Satellite Symposium 14 nov 2015 A Pintiaux ULg

Tissue-selective estrogen complexes for postmenopausal women. BMS Satellite Symposium 14 nov 2015 A Pintiaux ULg Tissue-selective estrogen complexes for postmenopausal women BMS Satellite Symposium 14 nov 2015 A Pintiaux ULg Effects of CEE in Post Menopausal Women with Hysterectomy CHD 0.91 ( 0.75-1.12 ) BC 0.77

More information

CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology

CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology A 49-year-old woman complains of irregular menses over the past 6 months, feelings of inadequacy, vaginal dryness, difficulty sleeping, and episodes

More information

Preventing Breast Cancer in HT users by Manuel Neves-e-Castro Portuguese Menopause Society September 2004

Preventing Breast Cancer in HT users by Manuel Neves-e-Castro Portuguese Menopause Society September 2004 Preventing Breast Cancer in HT users by Manuel Neves-e-Castro Portuguese Menopause Society September 2004 I am also PRO!... because HT does not increase breast cancer, and overall, its benefits out weight

More information

Appendix: Reference Table of HT Brand Names

Appendix: Reference Table of HT Brand Names Appendix: Reference Table of HT Brand Names This is a full reference table in alphabetical order, of Brand Name drugs used in HT. It is the basis for prescription advice throughout this handbook. Drug

More information

AusPharm CE Hormone therapy 23/09/10. Hormone therapy

AusPharm CE Hormone therapy 23/09/10. Hormone therapy Hormone therapy Learning objectives: Assess options to address quality of life and health concerns of menopausal women Outline indications for hormone therapy Counsel women on the risks and benefits of

More information

Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD

Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD JoAnn V. Pinkerton, MD Professor of Obstetrics and Gynecology Director,

More information

REVIEW POSSIBLE DELETION OF MEDROXYPROGESTERONE FROM THE 14 TH WHO MODEL LIST OF ESSENTIAL MEDICINES

REVIEW POSSIBLE DELETION OF MEDROXYPROGESTERONE FROM THE 14 TH WHO MODEL LIST OF ESSENTIAL MEDICINES REVIEW POSSIBLE DELETION OF MEDROXYPROGESTERONE FROM THE 14 TH WHO MODEL LIST OF ESSENTIAL MEDICINES Author: Lenita Wannmacher Application: To perform a quick review of medroxyprogesterone acetate tablet

More information

Bioidentical Hormones: Just the Facts

Bioidentical Hormones: Just the Facts Bioidentical Hormones: Just the Facts Melissa McNeil, MD, MPH Professor of Medicine and Obstetrics, Gynecology and Reproductive Sciences Chief, Section of Women s Health University of Pittsburgh Disclosures!

More information

The 6 th Scientific Meeting of the Asia Pacific Menopause Federation

The 6 th Scientific Meeting of the Asia Pacific Menopause Federation Predicting the menopause The menopause marks the end of ovarian follicular activity and is said to have occurred after 12 months amenorrhoea. The average age of the menopause is between 45 and 60 years

More information

Low & Ultra Low Dose HRT The Cardiovascular Impact

Low & Ultra Low Dose HRT The Cardiovascular Impact Low & Ultra Low Dose HRT The Cardiovascular Impact Wyeth Symposium, Turin 29 th Sept 2007 Nick Panay Consultant Gynaecologist Queen Charlotte s & Chelsea and Chelsea & Westminster Hospitals Honorary Senior

More information

Post-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018

Post-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018 Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma

More information

Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy

Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy MENOPAUSE Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy James H. Pickar, M.D., a I-Tien Yeh, M.D., b Gloria Bachmann, M.D.,

More information

5. Summary of Data Reported and Evaluation

5. Summary of Data Reported and Evaluation 326 5. Summary of Data Reported and Evaluation 5.1 Exposure data Combined estrogen progestogen menopausal therapy involves the co-administration of an estrogen and a progestogen to peri- or postmenopausal

More information

Menopausal Management: What Has Changed?

Menopausal Management: What Has Changed? Menopausal Management: What Has Changed? Julia V. Johnson, M.D. Professor and Chair, OB/GYN University of Massachusetts Medical School UMass Memorial Medical Center Conflicts of Interest None Learning

More information

Hormone replacement therapy in young women with karyotypically normal spontaneous premature ovarian failure [protocol]

Hormone replacement therapy in young women with karyotypically normal spontaneous premature ovarian failure [protocol] Página 1 de 7 Hormone replacement therapy in young women with karyotypically normal spontaneous premature ovarian failure [protocol] Kalantaridou SN, Calis KA, Nelson LM. This protocol should be cited

More information

Hormone therapy for menopausal vasomotor symptoms

Hormone therapy for menopausal vasomotor symptoms Hormone therapy for menopausal vasomotor symptoms Given our available (better) options for treating hot flashes, can we reduce our use of medroxyprogesterone acetate? OBG Manag. 2014;26(7):10,13 15. Robert

More information

Ms. Y. Outline. Updates of SERMs and Estrogen

Ms. Y. Outline. Updates of SERMs and Estrogen Ms. Y Updates of SERMs and Estrogen Steven R. Cummings, MD, FACP San Francisco Coordinating Center CPMC Research Institute and UCSF Support from Lilly, Pfizer, Berlex 55 y.o. woman with mild hypertension

More information

Hormones. Synthetic. Bioidentical. vs. SPECIAL REPORT. for Menopause. by Dr. Mark Stengler

Hormones. Synthetic. Bioidentical. vs. SPECIAL REPORT. for Menopause.  by Dr. Mark Stengler SPECIAL REPORT Synthetic vs. Bioidentical Hormones for Menopause by Dr. Mark Stengler www.markstengler.com All rights reserved. This program, or parts thereof, may not be reproduced in any form without

More information

W hile the headline-grabbing Women s

W hile the headline-grabbing Women s OBG MANAGEMENT BY ROBERT L. BARBIERI, MD New options in osteoporosis therapy: Combination and sequential treatment Perhaps the biggest medical question to emerge from the WHI study is how to best treat

More information

HRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD

HRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD Strong Bone Asia V. Osteoporosis in ASEAN (+), Danang, Vietnam, 3 August 2013 Management of osteoporosis and controversial issues HRT and bone health Delfin A. Tan, MD Section of Reproductive Endocrinology

More information

Southern California Center for Sexual Health and Survivorship Medicine Inc, Newport Beach, CA 3

Southern California Center for Sexual Health and Survivorship Medicine Inc, Newport Beach, CA 3 The WISDOM survey: Physicians Level of Comfort Prescribing Treatment for Vulvar and Vaginal Atrophy (VVA) Symptoms in Women with a Predisposition or History of Breast Cancer Lisa Larkin, MD 1 ; Michael

More information

Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome

Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome Endocrine Journal 2007, 54 (2), 233 238 Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome TAKESHI IWASA, TOSHIYA MATSUZAKI, MASAHIRO MINAKUCHI, NAOKO

More information

OVERVIEW OF MENOPAUSE

OVERVIEW OF MENOPAUSE OVERVIEW OF MENOPAUSE Nicole Budrys, MD, MPH Reproductive Endocrinology Michigan Center for Fertility and Women s Health Presented at SEMCME March 13,2019 Objectives Define menopause Etiology of menopause

More information

HKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 Revised November BENEFITS OF HRT

HKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 Revised November BENEFITS OF HRT HKCOG Guidelines Guidelines for the Administration of Hormone Replacement Therapy Number 2 Revised November 2006 Published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College

More information

HKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 revised January 2003

HKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 revised January 2003 HKCOG Guidelines Guidelines for the Administration of Hormone Replacement Therapy Number 2 revised January 2003 published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College

More information

OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc.

OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. Napa, California IMPORTANT SAFETY INFORMATION ABOUT EVAMIST: WARNING: ENDOMETRIAL CANCER,

More information

Menopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition

Menopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition Hormone Therapy Products Available in Canada for the Treatment of Menopausal Symptoms Physician Desk Reference - 3rd Edition A clinical resource provided to you by: The Society of Obstetricians and Gynaecologists

More information

Premature Menopause : Diagnosis and Management

Premature Menopause : Diagnosis and Management Guideline Number 3 : August 2010 Premature Menopause : Diagnosis and Management Introduction : Premature menopause is a serious condition that affects young women and remains an enigma. The challenges

More information

The Practice Committee of the American Society for Reproductive Medicine,

The Practice Committee of the American Society for Reproductive Medicine, FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. PRACTICE COMMITTEE Estrogen

More information

Research Article The Treatment with Hormone Replacement Therapy and Phytoestrogens and The Evolution of Urogenital Symptoms in Postmenopausal Women

Research Article The Treatment with Hormone Replacement Therapy and Phytoestrogens and The Evolution of Urogenital Symptoms in Postmenopausal Women Cronicon OPEN ACCESS PHARMACEUTICAL SCIENCE Research Article The Treatment with Hormone Replacement Therapy and Phytoestrogens and The Evolution of Urogenital Symptoms Bungau S 1, Tit DM 1 *, Fodor K 1

More information

Disclosures. REPLENISH Trial: Objective and Design. Background Use of compounded bioidentical hormone therapy (CBHT) has become highly prevalent

Disclosures. REPLENISH Trial: Objective and Design. Background Use of compounded bioidentical hormone therapy (CBHT) has become highly prevalent 17β Estradiol/Progesterone in a Single Oral Softgel Capsule (TX 001HR) Significantly Reduced Moderate to Severe Vasomotor Symptoms without Endometrial Hyperplasia Disclosures Research support: Actavis,

More information

Hormonal Control of Human Reproduction

Hormonal Control of Human Reproduction Hormonal Control of Human Reproduction Bởi: OpenStaxCollege The human male and female reproductive cycles are controlled by the interaction of hormones from the hypothalamus and anterior pituitary with

More information

HT: Where do we stand after WHI?

HT: Where do we stand after WHI? HT: Where do we stand after WHI? Hormone therapy and cardiovascular disease risk Experimental and clinical evidence indicate that hormone therapy (HT) reduces the risk of cardiovascular disease (CVD) Women

More information

Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice

Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and

More information

Columbia University Medical Center, New York, NY 2. Clinical Research Center, Eastern Virginia Medical School, Norfolk, VA 3

Columbia University Medical Center, New York, NY 2. Clinical Research Center, Eastern Virginia Medical School, Norfolk, VA 3 17β-Estradiol/Progesterone in a Single Oral Softgel Capsule (TX-001HR) Significantly Reduced Moderate-to-Severe Vasomotor Symptoms without Endometrial Hyperplasia Rogerio A Lobo, MD 1 ; David F Archer,

More information

Hormone. Free Androgen Index. 2-Hydroxyestrone. Reference Range. Hormone. Estrone Ratio. Free Androgen Index

Hormone. Free Androgen Index. 2-Hydroxyestrone. Reference Range. Hormone. Estrone Ratio. Free Androgen Index Hormonal Health PATIENT: Sample Report TEST REF: TST-12345 Hormonal Health 0.61 0.30-1.13 ng/ml DHEA-S 91 35-430 mcg/dl tient: SAMPLE TIENT e: x: N: Sex Binding Globulin 80 18-114 nmol/l Testosterone 0.34

More information

Therapeutic Cohort Results

Therapeutic Cohort Results Patient: SAMPLE PATIENT DOB: Sex: MRN: Menopause Plus - Salivary Profile Therapeutic Cohort Results Hormone Average Result QUINTILE DISTRIBUTION 1st 2nd 3rd 4th 5th Therapeutic Range* Estradiol (E2) 8.7

More information

IT IS WELL KNOWN that the decrease in circulating estradiol

IT IS WELL KNOWN that the decrease in circulating estradiol 0021-972X/00/$03.00/0 Vol. 85, No. 3 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society Close Correlation between Estrogen Treatment and Renal

More information

Deciding whether or not to use Hormone Therapy (HT) is a big decision and should be

Deciding whether or not to use Hormone Therapy (HT) is a big decision and should be Deciding whether or not to use Hormone Therapy (HT) is a big decision and should be made with input from your healthcare provider. After the decision has been made to take HT, many women don t realize

More information

ESTRADIOL LEVELS AND SERUM LIPIDS

ESTRADIOL LEVELS AND SERUM LIPIDS ESTRADIOL LEVELS AND SERUM LIPIDS Frank Z. Stanczyk et al. American Journal of OB/GYN, Volume 159, No. 6 A Randomized Comparison of Non Oral Estradiol Delivery in Post-Menopausal Women. Pellets produce

More information

Hormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase

Hormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase Patient Name: Patient DOB: Gender: Physician: Test Hormone Balance - Female Report SAMPLE Grote, Mary Jane Batch Number: B6437 2/16/1954 Accession Number: N52281 F Date Received: 2/3/2015 Any Lab Test

More information

WEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital

WEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased

More information

Hormone therapy. Dr. med. Frank Luzuy

Hormone therapy. Dr. med. Frank Luzuy Hormone therapy Dr. med. Frank Luzuy Reasons for Initiating/Continuing HT* Menopause-Related Symptoms Osteoporosis, Bone Loss, Fracture Prevention Doctor Prescribed It, Told Me to Take It Cardiovascular

More information

Postmenopausal hormone therapy - cardiac disease risks and benefits

Postmenopausal hormone therapy - cardiac disease risks and benefits Postmenopausal hormone therapy - cardiac disease risks and benefits Tomi S. Mikkola, MD Helsinki University Central Hospital Department of Obstetrics and Gynecology Helsinki, Finland Disclosures Speaker/consulting

More information

New products and regimens (since 2003)

New products and regimens (since 2003) CLIMACTERIC 2007;10(Suppl 2):109 114 New products and regimens (since 2003) N. West London Menopause & PMS Centre, London, UK Key words: HORMONE REPLACEMENT THERAPY, ULTRA-LOW-DOSE THERAPY, TRANSDERMAL

More information

Female Sexual Hormones Indications and Therapy

Female Sexual Hormones Indications and Therapy Female Sexual Hormones Indications and Therapy In puberty, a woman has about 400,000 ovules, at the age of 40-44 years about 17,000 only. On average, each grown-up woman (still having ovulation) loses

More information

Estrogen and progestogen therapy in postmenopausal women

Estrogen and progestogen therapy in postmenopausal women Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone

More information

Jim Paoletti BS Pharmacy, FAARM, FIACP, Director of Education, P2P

Jim Paoletti BS Pharmacy, FAARM, FIACP, Director of Education, P2P presents Converting Patients from Conventional Pioneering Technologies For to Bioidentical Lifestyle Based Medicine Hormone Therapy with Jim Paoletti BS Pharmacy, FAARM, FIACP, Director of Education, P2P

More information

Hysterectomy with Preservation of both Ovaries does not Result in Premature Ovarian Failure

Hysterectomy with Preservation of both Ovaries does not Result in Premature Ovarian Failure The Journal of International Medical Research 2007; 35: 416 421 Hysterectomy with Preservation of both Ovaries does not Result in Premature Ovarian Failure V ATAY 1, T CEYHAN 2, İ BASER 2, S GUNGOR 2,

More information

QUERIES: to be answered by AUTHOR

QUERIES: to be answered by AUTHOR Manuscript Information Climacteric Journal Acronym Volume and issue Author name Manuscript No. (if applicable) DCLI _A_254789 Typeset by KnowledgeWorks Global Ltd. for QUERIES: to be answered by AUTHOR

More information

Medroxyprogesterone increases basal temperature: a placebo-controlled crossover trial in postmenopausal women*

Medroxyprogesterone increases basal temperature: a placebo-controlled crossover trial in postmenopausal women* FERTILITY AND STERILITY Copyright 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Medroxyprogesterone increases basal temperature: a placebo-controlled crossover

More information

Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes*

Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes* FERTILITY AND STERILITY Vol. 59, No.5, May 1993 Copyright e 1993 The American Fertility Society Printed on acid-free paper in U.S.A. Prevention of endometrial hyperplasia by progesterone during long-term

More information

Current Topics in Hormone Replacement Therapy

Current Topics in Hormone Replacement Therapy Current Topics in Hormone Replacement Therapy Corey R. Babb, D.O., FACOOG, IF, NCMP Clinical Assistant Professor of Obstetrics and Gynecology Director of the Oklahoma State University Center for Women

More information

2004 OUTLOOK ON HORMONE REPLACEMENT THERAPY

2004 OUTLOOK ON HORMONE REPLACEMENT THERAPY La Rivista Italiana di Ostetricia e Ginecologia - Vol. 1 - pp. 5/10 International corner - pag.5 INTERNATIONAL CORNER 2004 OUTLOOK ON HORMONE REPLACEMENT THERAPY Andrea R. Genazzani, Marco Gambacciani

More information

UPDATE: Women s Health Issues

UPDATE: Women s Health Issues UPDATE: Women s Health Issues Renee B. Alexis, MD, MBA, MPH, FACOG Associate Professor Department of OBGYN Kiran C. Patel College of Osteopathic Medicine Disclosure of Conflicts of Interest I have no financial

More information

Kathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School

Kathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review

More information

the cumulative rates of persistence with estrogen replacement therapy, CEE/MPA and tibolone;

the cumulative rates of persistence with estrogen replacement therapy, CEE/MPA and tibolone; Economic impact of tibolone compared with continuous-combined hormone replacement therapy in the management of climacteric symptoms in postmenopausal women Diaby V, Perreault S, Lachaine J Record Status

More information

One Day Hormone Check

One Day Hormone Check One Day Hormone Check DOB: Sex: F MRN: Order Number: Completed: Received: Collected: Salivary Hormone Results Estradiol pmol/l >3330.0 Testosterone pmol/l

More information

A Practitioner s Toolkit for the Management of the Menopause

A Practitioner s Toolkit for the Management of the Menopause Medicine, Nursing and Health Sciences A Practitioner s Toolkit for the Management of the Menopause Developed by the Women s Health Research Program School of Public Health and Preventive Medicine Monash

More information

Therapeutic Cohort Results

Therapeutic Cohort Results Patient: JANE DOE DOB: December 31, 1968 Sex: F MRN: Order Number: Completed: February 26, 2016 Received: February 26, 2016 Collected: February 26, 2016 One Day Hormone Check - Salivary Profile Therapeutic

More information

Practical recommendations for hormone replacement therapy in the peri- and postmenopause

Practical recommendations for hormone replacement therapy in the peri- and postmenopause CLIMACTERIC 2004;7:in press Practical recommendations for hormone replacement therapy in the peri- and postmenopause Recommendations from an Expert Workshop, February 2004 Henry Burger, Australia; David

More information

SAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN:

SAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN: Patient: Age: 40 Sex: F MRN: SAMPLE PATIENT Order Number: Completed: Received: Collected: SAMPLE REPORT Progesterone ng/ml 0.34 0.95 21.00 DHEA-S mcg/dl Testosterone ng/ml 48 35 0.10 0.54 0.80 430 Sex

More information

Menopausal hormone therapy currently has no evidence-based role for

Menopausal hormone therapy currently has no evidence-based role for IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),

More information

CHANGES IN MAMMOGRAPHIC AND ULTRASOUND IMAGE OF THE BREAST OF WOMEN UNDERGOING ESTROGEN REPLACEMENT THERAPY

CHANGES IN MAMMOGRAPHIC AND ULTRASOUND IMAGE OF THE BREAST OF WOMEN UNDERGOING ESTROGEN REPLACEMENT THERAPY Biomed. Papers 147(2), 211 219 (2003) D. Houserková, J. Matlochová, M. Hartlová 211 CHANGES IN MAMMOGRAPHIC AND ULTRASOUND IMAGE OF THE BREAST OF WOMEN UNDERGOING ESTROGEN REPLACEMENT THERAPY Dana Houserková

More information

22/09/2014. Menopause Management. Menopause. Menopause symptoms

22/09/2014. Menopause Management. Menopause. Menopause symptoms Menopause Management Dr Sonia Davison Jean Hailes for Women s Health Menopause Time of last menstrual period - average age 51 Premature Menopause: occurs before age 40 Perimenopause (menopause transition):

More information

Benton Franklin County Medical Society 31st Annual CME Seminar

Benton Franklin County Medical Society 31st Annual CME Seminar Management of Current HT/ET and SERM Recommendations Benton Franklin County Medical Society 31st Annual CME Seminar February 21, 2015 Kennewick, Washington Spokane steoporosis Dr. Lynn Kohlmeier Lynn Kohlmeier,

More information

2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK

2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK 2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK WHI the only large, long-term RCT of HT in women aged 50 to 79 years, Drug trail

More information

EVALUATION OF WOMEN FOLLOWING HYSTERECTOMY WITH AND WITHOUT CONSERVATION OF OVARIES

EVALUATION OF WOMEN FOLLOWING HYSTERECTOMY WITH AND WITHOUT CONSERVATION OF OVARIES Int. J. Chem. Sci.: 6(3), 2008, 1228-1235 EVALUATION OF WOMEN FOLLOWING HYSTERECTOMY WITH AND WITHOUT CONSERVATION OF OVARIES RAMPRASAD DEY, SUBHASH CHANDRA BISWAS, RANU ROY BISWAS a and ARUNIMA MUKHOPADHYAY

More information

Therapeutic Cohort Results

Therapeutic Cohort Results Patient: PAGE LOVE DOB: January 11, 1983 Sex: F MRN: 1232704193 Order Number: J9020008 Completed: July 08, 2016 Received: July 02, 2016 Collected: July 01, 2016 Aum Healing Center Sarika Arora MD 332 Newbury

More information

MENOPAUSAL HORMONE THERAPY 2016

MENOPAUSAL HORMONE THERAPY 2016 MENOPAUSAL HORMONE THERAPY 2016 Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA NICE provides the National Health Service advice on effective, good value healthcare.

More information

One Day Hormone Check

One Day Hormone Check One Day Hormone Check Patient: EMILY TEST DOB: January 18, 1948 Sex: F MRN: 0000000004 Order Number: J5070009 Completed: March 07, 2014 Received: March 07, 2014 Collected: March 07, 2014 Alec Smart, ND

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Ultra-Sensitive Estradiol lumelisa Catalog No. GWB-AEB745, legacy id (96 Tests)

Ultra-Sensitive Estradiol lumelisa Catalog No. GWB-AEB745, legacy id (96 Tests) For Research Use Only. Not for use in Diagnostic Procedures. INTENDED USE The GenWay, Inc. Ultra Sensitive Estradiol (E2) (Chemiluminescence Enzyme Linked Immunosorbent Assay) is used for the ultra sensitive

More information

An Evidence-based Review of Clinical Trial Data

An Evidence-based Review of Clinical Trial Data An Evidence-based Review of Clinical Trial Data Karen K. Miller, MD Massachusetts General Hospital Harvard Medical School Boston, MA 1 Rationale for Investigating Androgen Administration in Women: Data

More information

OBSTETRICS & GYNECOLOGY

OBSTETRICS & GYNECOLOGY AUGUST 2011 NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING N ORLANDA VENUEP HARMACY. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: BHRT for Menopause

More information

Evaluation Of The Efficacy And Tolerability Of Micronutrient Supplementation In Treatment Of Post Menopausal Symptoms

Evaluation Of The Efficacy And Tolerability Of Micronutrient Supplementation In Treatment Of Post Menopausal Symptoms ISPUB.COM The Internet Journal of Genomics and Proteomics Volume 6 Number 2 Evaluation Of The Efficacy And Tolerability Of Micronutrient Supplementation In Treatment Of Post S Pandit, S Umbardand, V Ghodake,

More information